drugset / Trial / NCT04833036
c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary endpoint is to evaluate the progression-free survival (PFS).
Timeline
- Start
- 2019-10-01
- Primary completion
- 2022-01
- Completion
- 2022-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |